Patent ID: 9370512
Filing Date: 2016-06-21
CPC Classification: A61K,A61P

Claim Text:
1. A method of opioid substitution therapy for treating opioid addiction, the method comprising contacting the sublingual mucosa of a patient in need thereof with a sublingual film dosage form comprising: a) approximately 0.1 mg to approximately 16 mg buprenorphine, or an equivalent amount of a pharmaceutically acceptable salt thereof; b) naloxone or a pharmaceutically acceptable salt thereof; and c) at least one non-gelatin polymeric film-forming material in which the buprenorphine or the equivalent amount of the pharmaceutically acceptable salt thereof and the naloxone or the pharmaceutically acceptable salt thereof, are dissolved or homogeneously dispersed; the buprenorphine or the equivalent amount of the pharmaceutically acceptable salt thereof and the naloxone or the pharmaceutically acceptable salt thereof being present in the sublingual film dosage form in a weight ratio of from 1:1 to 10:1; such that within less than 5 minutes after contacting the sublingual mucosa of the patient with the sublingual film dosage form, the buprenorphine or the pharmaceutically acceptable salt thereof and approximately substantially all of the naloxone or the pharmaceutically acceptable salt thereof contact the sublingual mucosa, and wherein said contacting achieves: (i) an average buprenorphine AUC (ii) an average buprenorphine AUC (iii) an average buprenorphine AUC